|
Market Closed -
Nasdaq
16:00:00 2026-09-09 EDT
|
5-day change | 1st Jan Change | ||
| 4.110 USD | -4.86% |
|
+1.73% | +155.28% |
| 08-17 | B. Riley Raises Price Target on MacroGenics to $11 From $9, Keeps Buy Rating | MT |
| 08-13 | MacroGenics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 | CI |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Compared values
| Sector | Change | 5-day change | YTD change | 1-year change | 5-year change | Capi. | ST | MT | LT | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| MACROGENICS, INC. | Bio Therapeutic Drugs | -4.86% | +1.73% | +155.28% | +133.52% | -80.54% | 275M |  | | |
- Stock Market
- Stocks
- MGNX Stock
- Charts MacroGenics, Inc.
- Comparison Chart
Select your edition
All financial news and data tailored to specific country editions
